Sanofi builds case for Toujeo in younger type 1 diabeticsSanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but Share XSanofi builds case for Toujeo in younger type 1 diabeticshttps://pharmaphorum.com/news/sanofi-builds-case-for-toujeo-in-younger-type-1-diabetics/
Lilly and Boehringer rejig diabetes alliance as Jardiance soarsEli Lilly and Boehringer Ingelheim have changed the terms of their diabetes alliance to focus their energies on Share XLilly and Boehringer rejig diabetes alliance as Jardiance soarshttps://pharmaphorum.com/news/lilly-and-boehringer-rejig-diabetes-alliance-as-jardiance-soars/
CHMP backs Lilly’s Baqsimi as non-injectable for severe low blood sugarThe EMA’s human medicines advisory committee has recommended approval of Eli Lilly’s Baqsimi as the first needle-free treatment Share XCHMP backs Lilly’s Baqsimi as non-injectable for severe low blood sugarhttps://pharmaphorum.com/news/chmp-backs-lillys-baqsimi-as-non-injectable-for-severe-low-blood-sugar/
FDA approves AZ’s Farxiga in new heart failure prevention useThe FDA has approved AstraZeneca’s diabetes drug Farxiga to reduce the chances of hospitalisations for heart failure in Share XFDA approves AZ’s Farxiga in new heart failure prevention usehttps://pharmaphorum.com/news/fda-approves-azs-farxiga-in-new-heart-failure-prevention-use/
Artificial pancreas outperforms current tech in type 1 diabetesAn “artificial pancreas” has proved to be more effective at controlling blood sugar than injections with insulin by Share XArtificial pancreas outperforms current tech in type 1 diabeteshttps://pharmaphorum.com/news/artificial-pancreas-outperforms-current-tech-in-type-1-diabetes/
Pfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drugPfizer has signed a deal with Ionis’ affiliate Akcea Therapeutics, to develop a potential blockbuster antisense therapy to Share XPfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drughttps://pharmaphorum.com/news/pfizer-inks-deal-with-ionis-and-akcea-for-potential-blockbuster-diabetes-and-nash-drug/
Novo’s new oral GLP-1 Rybelsus still has obstacles to overcomeThe FDA approval last Friday of Novo Nordisk’s Rybelsus as the first orally-active GLP-1 agonist is only the Share XNovo’s new oral GLP-1 Rybelsus still has obstacles to overcomehttps://pharmaphorum.com/news/novos-new-oral-glp-1-still-has-obstacles-to-overcome/
Novo and Sanofi make case for hypo-reducing insulins at EASDNovo Nordisk and Sanofi have gone head-to-head at this week’s European diabetes conference, with the two arch rivals Share XNovo and Sanofi make case for hypo-reducing insulins at EASDhttps://pharmaphorum.com/news/novo-and-sanofi-duke-it-out-at-easd-making-case-for-hypo-reducing-insulins/
Giving patients a sense of belongingClinical research professional and patient advocate Kristina Wolfe tells us how pharma can collaborate better with patients and Share XGiving patients a sense of belonginghttps://pharmaphorum.com/views-analysis-patients/giving-patients-a-sense-of-belonging/
